IDFX:LSE:LSE-iShares China Large Cap UCITS (USD)

ETF | Others |

Last Closing

USD 90.955

Change

+0.59 (+0.65)%

Market Cap

N/A

Volume

0.01M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-30 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
0R1O:LSE Amazon.com Inc.

-4.75 (-2.49%)

USD 1,607.29B
0R1I:LSE NVIDIA Corp.

-0.84 (-0.70%)

USD 618.20B
LCJD:LSE Amundi MSCI Japan (DR) UCITS E..

-0.08 (-0.45%)

USD 572.76B
LCJP:LSE Lyxor Core MSCI Japan (DR) UCI..

-0.05 (-0.38%)

USD 572.76B
0R1G:LSE Home Depot Inc.

N/A

USD 373.16B
0QZK:LSE Coca-Cola Co.

-0.25 (-0.35%)

USD 266.08B
0QZO:LSE 0QZO

-1.05 (-1.09%)

USD 258.54B
0QZ3:LSE Qualcomm Inc.

-4.82 (-2.77%)

USD 202.26B
PRJU:LSE Amundi Index Solutions - Amund..

-0.12 (-0.38%)

USD 200.79B
0R24:LSE Intel Corp.

-0.35 (-1.47%)

USD 196.14B

ETFs Containing IDFX:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 32.13% 96% N/A 92% A
Dividend Return 2.76% 74% C 86% B+
Total Return 34.89% 96% N/A 92% A
Trailing 12 Months  
Capital Gain 22.63% 70% C- 69% C-
Dividend Return 2.56% 63% D 80% B-
Total Return 25.19% 74% C 72% C
Trailing 5 Years  
Capital Gain -18.53% 12% F 26% F
Dividend Return 5.58% 58% F 70% C-
Total Return -12.95% 12% F 26% F
Average Annual (5 Year Horizon)  
Capital Gain -9.68% N/A N/A 14% F
Dividend Return -8.72% N/A N/A 15% F
Total Return 0.96% N/A N/A 71% C-
Risk Return Profile  
Volatility (Standard Deviation) 17.16% N/A N/A 58% F
Risk Adjusted Return -50.82% N/A N/A 15% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike